摘要:
The present disclosure describes Boswellia low polar gum resin extract (BLPRE) comprising novel phytochemical composition of sesquiterpenes, diterpenes, triterpenes and other phytochemical(s) obtained from gum resin of Boswellia species. The present disclosure also describes compositions comprising BLPRE in combination with one or more component(s) selected from biologically active ingredient(s), functional ingredient(s), excipient(s), diluents(s), carrier(s) and additive(s) or mixtures thereof. Further the present disclosure also provides synergistic composition(s) comprising Boswellia low polar gum resin extract (BLPRE) and at least one component selected from but not limited to extract(s), fraction(s), phytochemical(s) or their salts or mixtures thereof derived from Boswellia species or Curcuma species.
摘要:
The invention discloses phytochemical agents derived from Holoptelea integrifolia and novel composition(s) comprising at least one component selected from the extract(s), fraction(s) and active compound(s) for the protection and alleviation of Metabolic Syndrome, insulin resistance, endothelial dysfunction, chronic kidney disease, atherosclerosis, diabetes and other disease conditions associated with metabolic syndrome. The invention also discloses the amelioration of certain biomarker molecules such as Peroxisome proliferator-activated receptor gamma (PPAR-γ), Adipose Differentiation Related Protein (ADRP), CD36, Adipocyte Fatty-acid-Binding Protein (aP2/FABP-4/A-FABP), beta-3 Adrenergic Receptor (β3AR), Leptin, Perilipin and Adiponectin by using the phytochemical components derived from Holoptelea integrifolia.
摘要:
Disclosed herein are novel dietary supplement compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid and enriched demethylated curcuminoids, wherein the composition exhibits anti-inflammatory, antiulcerogenic and anti-oxidant activities. Also disclosed are novel compositions comprising enriched 3-O-acetyl-11-keto-β-boswellic acid, enriched demethylated curcuminoids that have a synergistic effect on specific inhibition of—COX-2 and 5-LOX activity and optionally containing glucosamine, resveratrol, garlic extract, chondroitin, methlysulphonymethane, bromelain, serratiopeptidase, quercitine, gallic acid, caffeic acid, green tea extract, aspirin and ibuprofen.
摘要:
Selenopheno triazene analogs, their compositions, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts and mixtures thereof are useful for the treatment of metastatic malignant melanoma and other cancers. The selenopheno triazene analogs have the general formulae (I) or (II): wherein the substituents R1, R2, R3, R6, and R7 are as described in the specification. Other cancers include which may be treated with these compounds include, but are not limited to, malignant melanoma, leukemia, lymphomas (Hodgkins and non-Hodgkins), sarcomas (Ewing's sarcoma), brain tumors, central nervous system (CNS) metastases, gliomas, carcinomas such as breast cancer, prostate cancer, lung cancer (small cell and non-small cell), colon cancer, pancreatic cancer, Head and Neck cancers and oropharyngeal squamous cell carcinoma.
摘要:
A process for nanomulsification of highly lipophillic polyphenols compounds using non-ionic surfactant and a non-ionic co-solvent with the help of sonar energy, to enhance the aqueous solubility is disclosed herein.
摘要:
The present invention discloses synergistic nutraceutical or pharmaceutical or dietary supplement anti-inflammatory compositions comprising therapeutically effective combination of an extract selectively enriched in 3-O-acetyl-11-keto-β-boswellic acid (AKBA) derived from Boswellia serrata and Boswellia serrata non- acidic resin extract (BNRE). The composition(s) can be used to prevent, control and treat inflammation and several inflammatory related diseases including asthma, osteoarthritis, rheumatoid arthritis, endothelial dysfunction and the like. The invention further discloses the amelioration of pro-inflammator biomarker proteins or molecules, whose expression/production is altered during inflammatory diseases.
摘要:
The invention discloses a compound of formula (I) wherein, at least one of R1, R2, R3 and R4 is —C(═O)Rn and R1, R2R3 and R4 are H or CH3 and Rn is alkyl or alkenyl group. The alkenyl group have one or more number of double bonds either in cis form or trans form or both. In Rn, where n is 12 to 30 carbons; and pharmaceutically acceptable salt thereof. The said alkenyl groups are preferably selected from the group consisting of eicosapentaenoic acid (EPA) or DHA (docosahexaenoic acid). This invention further discloses processes for their preparation of compounds of formula I and pharmaceutical compositions that contain these compounds.
摘要:
The current disclosure discloses acetogenin(s), extract(s)/fraction(s) standardized to acetogenin(s) comprising terminal α,β-unsaturated-γ-methyl-γ-lactone moiety derived from Annona squamosa or their compositions for prevention, treatment, inhibition or controlling inflammation and immune related diseases or disorders mediated through cytokines/chemokines or other biomarkers. The disclosure further discloses said Annona squamosa derived acetogenin(s), extract(s)/fraction(s) or their compositions for prevention, treatment, inhibition or controlling metabolic diseases/disorders.
摘要:
Pharmaceutical, cosmetic, nutraceutical and dietary compositions derived from Garcinia mangostana are rich in γ-mangostin and other demethylated xanthones. These compositions exhibit potent antioxidative activity and reduce inflammation. These compositions may be used in a method of treating TNF-α, and aP2 mediated disorders. The compositions are prepared by subjecting a hydroalcoholic extract of fruit pericarp (fruit hull) of Garcinia mangostana, wherein said hydroalcoholic extract comprises predominantly α-mangostin, to demethylation in the presence of a Lewis acid, an organic base and a catalyst.
摘要:
The present disclosure relates to non-acidic extracts or fractions selected from a Boswellia low polar gum resin extract fraction (BLPRE), a Boswellia volatile oil fraction (BVOIL), and a Boswellia oil fraction (BOIL) and their compositions. BLPRE, BOIL, and BVOIL are each derived from the gum resin of a Boswellia species. These compositions are useful for improving mental condition, enhancing brain functions such as cognition, memory, learning, communication and brain health, for treating impaired memory, and for preventing, control or treating memory and cognition related disorders/diseases. Additionally, BOIL, BVOIL, and mixtures of BOIL and BVOIL are useful for enhancing the bioavailability of a biological agent.